Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Bosentan Eyewash in Type 2 Diabetes
NCT04068272Phase 1Completed
- Sponsor
- Retinset
- Start
- Sep 2019
- Primary completion
- May 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bosentan in diabetic retinopathy (DR) (2 arms), sponsored by Retinset. Primary endpoint: Epitheliopathy at 1 month. Started Sep 2019; status: completed.
02
Drugs
bosentan
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT04068272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04068272.